

Application. No. 09/980,586  
Amendment dated November 30, 2003  
Reply to Restriction Requirement mailed May 29, 2003

### REMARKS/ARGUMENTS

Claims 98-122 are pending, claims 1-97 having been canceled and new claims 98-122 having been added. New claims 98-122 are directed to a method of treating Alzheimer's disease. Support for new claim 98 is provided at, e.g., page 5, line 31 to page 6, line 16 of the specification. Further support for new claim 98 is provided by original claims 39 and 40. Support for new claim 99 is provided by original claims 2 and 4. Support for new claim 100 is provided by original claims 5 and 40. Support for new claim 101 is provided by original claim 6. Support for new claim 102 is provided by original claim 20. Support for new claim 103 is provided by original claim 25. Support for new claim 104 is provided by original claim 9. Support for new claim 106 is provided by original claim 10. Support for new claim 113 is provided by original claim 18. Support for new claims 114 and 115 is provided by original claim 19. Support for new claim 116 is provided by original claim 43. Support for new claim 117 is provided by original claim 30. Support for new claim 118 is provided by original claim 44. Support for new claims 119-120 is provided by original claim 41. Thus, new claims 98-122 contain no new matter.


Applicants elected Group V with traverse. It is the Applicants position that in view of the claim amendments there is unity of invention at least for Groups V and VI.

The unifying technical feature between Groups V and VI resides in the provision of a method of using a sterile aqueous suspension comprising an A $\beta$  peptide effective to induce an immunogenic response comprising antibodies to the A $\beta$  peptide, and thereby prevent or treat Alzheimer's disease. This technical feature is also present in Group III because the claims recited a composition which is an example of a composition used in the method of the claims of Groups V and VI. This technical feature is also present in Group IV because the claims recite an example of a method of preparing a composition used in the method of the claims of Groups V and VI. Moreover, all of these groups have a technical relationship in that they are premised in part on the inventor's insight that antibodies to the A $\beta$  peptide are effective in the prevention or treatment of Alzheimer's disease.

Application No. 09/980,586  
Amendment dated November 30, 2003  
Reply to Restriction Requirement mailed May 29, 2003

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2400  
RLC:rlc  
60006572 v1